Role and targetability of RNA-binding proteins in prostate cancer drug resistance

Description of the granted funding

Cancer poses an increasing global burden. While advancements with better treatment options have increased patient survival times, formation of tumor resistance to currently available drugs is a prevailing challenge with many cancers. To overcome treatment resistance, therapies need to be designed to target the drug resistance mechanisms. Against prostate cancer, current drugs are initially effective. However, cancer cells often find a way to tolerate these drugs and form a resistance. In this project, we study how much does regulation of RNA molecules, the expression products of genes, provide the required flexibility for cancer cells to dodge the bullets during drug treatments. Especially, role of RNA-binding proteins in these processes is studied. The results of this research will help understand molecular mechanisms of cancer drug resistance and provide targets to design novel therapeutics against.
Show more

Starting year

2023

End year

2027

Granted funding

Leena Latonen Orcid -palvelun logo
520 345 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

357490

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

cancer